PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus.

Abstract This study, a subgroup analysis of the data from the Organization Program of DiabEtes INsulIN ManaGement study, aimed to compare the efficacy and safety profiles of acarbose and metformin used in combination with premixed insulin.This analysis included 80 and 192 patients taking only 1 oral antidiabetic drug, classified into acarbose (treated with acarbose + insulin) and metformin groups (treated with metformin + insulin), respectively. The efficacy and safety data were analyzed for within- and between-group differences. The clinical trial registry number was NCT01338376.The percentage of patients who achieved target hemoglobin A1c (HbA1c) <7% in the acarbose and metformin groups were 38.75% and 30.73%, respectively, after a 16-week treatment. The average HbA1c levels in the acarbose and metformin groups were comparable at baseline and decreased significantly in both groups at the end of the study. All 7 blood glucose decreased significantly in both groups at endpoint compared with that at baseline. Insulin consumption was higher in the metformin group in terms of total daily amount and units/kg body weight. Incidences of hypoglycemia were similar in both groups. Body weight changed significantly in both groups from baseline to endpoint, but with no significant difference between the groups. Mean scores of Morisky Medication Adherence Scale improved in both groups at endpoint.Combination of insulin with acarbose or metformin could improve glycemic control in patients with type 2 diabetes mellitus. Acarbose and metformin were found to be comparable in terms of efficacy, weight gain, and incidence of hypoglycemia.
PMID
Related Publications

Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.

Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28858080
OWN - NLM
STAT- In-Process
DA  - 20170831
LR  - 20170831
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 35
DP  - 2017 Sep
TI  - Comparative assessment of the efficacy and safety of acarbose and metformin
      combined with premixed insulin in patients with type 2 diabetes mellitus.
PG  - e7533
LID - 10.1097/MD.0000000000007533 [doi]
AB  - This study, a subgroup analysis of the data from the Organization Program of
      DiabEtes INsulIN ManaGement study, aimed to compare the efficacy and safety
      profiles of acarbose and metformin used in combination with premixed insulin.This
      analysis included 80 and 192 patients taking only 1 oral antidiabetic drug,
      classified into acarbose (treated with acarbose + insulin) and metformin groups
      (treated with metformin + insulin), respectively. The efficacy and safety data
      were analyzed for within- and between-group differences. The clinical trial
      registry number was NCT01338376.The percentage of patients who achieved target
      hemoglobin A1c (HbA1c) &lt;7% in the acarbose and metformin groups were 38.75% and
      30.73%, respectively, after a 16-week treatment. The average HbA1c levels in the 
      acarbose and metformin groups were comparable at baseline and decreased
      significantly in both groups at the end of the study. All 7 blood glucose
      decreased significantly in both groups at endpoint compared with that at
      baseline. Insulin consumption was higher in the metformin group in terms of total
      daily amount and units/kg body weight. Incidences of hypoglycemia were similar in
      both groups. Body weight changed significantly in both groups from baseline to
      endpoint, but with no significant difference between the groups. Mean scores of
      Morisky Medication Adherence Scale improved in both groups at
      endpoint.Combination of insulin with acarbose or metformin could improve glycemic
      control in patients with type 2 diabetes mellitus. Acarbose and metformin were
      found to be comparable in terms of efficacy, weight gain, and incidence of
      hypoglycemia.
FAU - Wu, Honghua
AU  - Wu H
AD  - aDepartment of Endocrinology, Peking University First Hospital, Beijing
      bDepartment of Endocrinology, Shanxi Provincial People's Hospital, Taiyuan
      cDepartment of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University,
      Hangzhou dDepartment of Endocrinology, Gansu Provincial People's Hospital,
      Lanzhou eDepartment of Endocrinology, Peking University People's Hospital,
      Beijing fDepartment of Endocrinology, Chinese PLA General Hospital, Beijing
      gDepartment of Endocrinology, Shanghai Pudong New Area Gongli Hospital, Shanghai,
      China.
FAU - Liu, Jie
AU  - Liu J
FAU - Lou, Qingqing
AU  - Lou Q
FAU - Liu, Jing
AU  - Liu J
FAU - Shen, Li
AU  - Shen L
FAU - Zhang, Mingxia
AU  - Zhang M
FAU - Lv, Xiaofeng
AU  - Lv X
FAU - Gu, Mingjun
AU  - Gu M
FAU - Guo, Xiaohui
AU  - Guo X
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
EDAT- 2017/09/01 06:00
MHDA- 2017/09/01 06:00
CRDT- 2017/09/01 06:00
AID - 10.1097/MD.0000000000007533 [doi]
AID - 00005792-201709010-00004 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Sep;96(35):e7533. doi: 10.1097/MD.0000000000007533.